Aegerion Pharmaceuticals (NASDAQ:AEGR) had its price objective hosited by Jefferies Group from $82.00 to $92.00 in a report released on Wednesday, StockRatingsNetwork reports. Jefferies Group currently has a buy rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank reiterated a buy rating on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They now have a $85.00 price target on the stock, down previously from $107.00. Finally, analysts at Canaccord Genuity raised their price target on shares of Aegerion Pharmaceuticals from $90.00 to $110.00 in a research note to investors on Wednesday. They now have a buy rating on the stock.
Nine analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average price target of $83.35.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 94.32 on Wednesday. Aegerion Pharmaceuticals has a 52 week low of $12.87 and a 52 week high of $97.46. The stock’s 50-day moving average is currently $72.43. The company’s market cap is $2.718 billion.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.